
Bo Carlberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6835549/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Vascular risk profiles for predicting outcome and long-term mortality in patients with idiopathic normal pressure hydrocephalus: comparison of clinical decision support tools. Journal of Neurosurgery, 2023, 138, 476-482.	0.9	1
2	Time to initiation of lipid-lowering drugs for subclinical atherosclerosis: sub-study of VIPVIZA randomized controlled trial, with single-arm cross-over. European Heart Journal Open, 2022, 2, .	0.9	2
3	Methodological Aspects of Meta-Analyses Assessing the Effect of Blood Pressure–Lowering Treatment on Clinical Outcomes. Hypertension, 2022, 79, 491-504.	1.3	11
4	Association of education and feedback on hypertension management with risk for stroke and cardiovascular disease. Blood Pressure, 2022, 31, 31-39.	0.7	2
5	Do recent meta-analyses truly prove that treatment with blood pressure-lowering drugs is beneficial at any blood pressure value, no matter how low? A critical review. Journal of Hypertension, 2022, 40, 839-846.	0.3	11
6	Survival after surgery of the ascending aorta: a matched cohort study. European Journal of Cardio-thoracic Surgery, 2022, 62, .	0.6	2
7	Prescribing blood pressure lowering drugs irrespective of blood pressure?. Journal of Hypertension, 2022, 40, 1050-1051.	0.3	0
8	Comparative efficacy and acceptability of different antihypertensive drug classes for cardiovascular disease prevention: protocol for a systematic review and network meta-analysis. BMJ Open, 2021, 11, e044302.	0.8	2
9	Prescription of Lipid-Lowering and Antihypertensive Drugs Following Pictorial Information About Subclinical Atherosclerosis. JAMA Network Open, 2021, 4, e2121683.	2.8	7
10	The beneficial effect over 3 years by pictorial information to patients and their physician about subclinical atherosclerosis and cardiovascular risk: Results from the VIPVIZA randomized clinical trial. American Journal of Preventive Cardiology, 2021, 7, 100199.	1.3	21
11	Weight gain and blood pressure. Journal of Hypertension, 2020, 38, 387-394.	0.3	7
12	Association of Physician Education and Feedback on Hypertension Management With Patient Blood Pressure and Hypertension Control. JAMA Network Open, 2020, 3, e1918625.	2.8	16
13	A multiple risk factor programÂis associated with decreased risk of cardiovascular disease in 70-year-olds: A cohort study from Sweden. PLoS Medicine, 2020, 17, e1003135.	3.9	10
14	Title is missing!. , 2020, 17, e1003135.		0
15	Title is missing!. , 2020, 17, e1003135.		0
16	Title is missing!. , 2020, 17, e1003135.		0
17	MYLK pathogenic variants aortic disease presentation, pregnancy risk, and characterization of pathogenic missense variants. Genetics in Medicine, 2019, 21, 144-151.	1.1	36
18	Benefits and harms of lower blood pressure treatment targets: systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open, 2019, 9, e026686.	0.8	11

BO CARLBERG

#	Article	IF	CITATIONS
19	Perspective From Sweden on the Global Impact of the 2017 American College of Cardiology/American Heart Association Hypertension Guidelines. Circulation, 2018, 137, 886-888.	1.6	20
20	Questionable Conclusions Regarding Blood Pressure End Points—Reply. JAMA Internal Medicine, 2018, 178, 575.	2.6	0
21	SPRINT in context. Journal of Hypertension, 2018, 36, 979-986.	0.3	6
22	Standardization according to blood pressure lowering in meta-analyses of antihypertensive trials. Journal of Hypertension, 2018, 36, 4-15.	0.3	9
23	Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels. JAMA Internal Medicine, 2018, 178, 28.	2.6	329
24	Aortic stiffness in families with inherited non-syndromic thoracic aortic disease. Scandinavian Cardiovascular Journal, 2018, 52, 301-307.	0.4	2
25	May Measurement Month, season 1. The Lancet Global Health, 2018, 6, e704-e705.	2.9	0
26	Vascular risk factors in INPH. Neurology, 2017, 88, 577-585.	1.5	77
27	Optimal Timing of Anticoagulant Treatment After Intracerebral Hemorrhage in Patients With Atrial Fibrillation. Stroke, 2017, 48, 314-320.	1.0	92
28	Time trends and socioeconomic differences in blood pressure levels: The Northern Sweden MONICA study 1994–2014. European Journal of Preventive Cardiology, 2017, 24, 1473-1481.	0.8	17
29	Decreasing prevalence of abdominal aortic aneurysm and changes in cardiovascular risk factors. Journal of Vascular Surgery, 2017, 65, 651-658.	0.6	30
30	A novel variant in MYLK causes thoracic aortic dissections: genotypic and phenotypic description. BMC Medical Genetics, 2016, 17, 61.	2.1	27
31	Aging alters the dampening of pulsatile blood flow in cerebral arteries. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 1519-1527.	2.4	84
32	From efficacy in trials to effectiveness in clinical practice: The Swedish Stroke Prevention Study. Blood Pressure, 2016, 25, 206-211.	0.7	3
33	Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ, The, 2016, 352, i717.	3.0	288
34	Lower blood pressure targets: to whom do they apply?. Lancet, The, 2016, 387, 405-406.	6.3	12
35	Long term trends in control of hypertension in the Northern Sweden MONICA study 1986–2009. BMC Public Health, 2015, 15, 957.	1.2	15
36	Screening for Familial Thoracic Aortic Aneurysms with Aortic Imaging Does Not Detect All Potential Carriers of the Disease. Aorta, 2015, 03, 1-8.	0.1	13

BO CARLBERG

#	Article	IF	CITATIONS
37	Blood Pressure, Gait Speed, and Mortality in Very Old Individuals: A Population-Based Cohort Study. Journal of the American Medical Directors Association, 2015, 16, 208-214.	1.2	33
38	Oral Appliance Therapy in Patients With Daytime Sleepiness and Snoring or Mild to Moderate Sleep Apnea. JAMA Internal Medicine, 2015, 175, 1278.	2.6	64
39	Antithrombotic Treatment Following Intracerebral Hemorrhage in Patients With and Without Atrial Fibrillation. Stroke, 2015, 46, 2094-2099.	1.0	49
40	Thrombolysis in acute stroke. Lancet, The, 2015, 385, 1394-1395.	6.3	12
41	The new Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014): a giant undertaking. Hypertension Research, 2014, 37, 391-392.	1.5	9
42	Proteinuria early in the development of hypertension. Journal of Hypertension, 2014, 32, 2351-2352.	0.3	0
43	Long-Term Risk and Predictors of Recurrent Stroke Beyond the Acute Phase. Stroke, 2014, 45, 1839-1841.	1.0	118
44	What do we know about the risks of stopping antihypertensive treatment?. Journal of Hypertension, 2014, 32, 1400-1401.	0.3	6
45	The challenge of preventing dementia by antihypertensive treatment. Journal of Hypertension, 2013, 31, 1780-1781.	0.3	Ο
46	Hypertension in the Elderly: What Is the Goal Blood Pressure Target and How Can This Be Attained?. Current Hypertension Reports, 2010, 12, 331-334.	1.5	6
47	Stroke and blood-pressure variation: new permutations on an old theme. Lancet, The, 2010, 375, 867-869.	6.3	17
48	Atenolol in hypertension: is it a wise choice?. Lancet, The, 2004, 364, 1684-1689.	6.3	503